Skip to content
drillr.ai
Sign up

MLTX

MoonLake Immunotherapeutics

NASDAQ · Healthcare · Biotechnology · CH

$12.15
−3.34%
Ask drillr

  • Oct 22, 2026, 18:23 UTC

    MoonLake Immunotherapeutics shares traded higher, with session volume of 4.20 million shares versus an average volume of 1.494 million.

    Source:

  • Aug 10, 2026, 11:00 UTC

    MoonLake Immunotherapeutics announced positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all clinical endpoints at Week 16, and reported second quarter 2026 financial results with $537.0 million in cash and cash equivalents as of the end of the quarter.

    Source:

  • Jun 24, 2026, 03:08 UTC

    MoonLake Immunotherapeutics priced an upsized $200 million public offering of 9,000,000 Class A ordinary shares and pre-funded warrants for up to 1,000,000 Class A ordinary shares.

    Source:

  • Jun 1, 2026, 00:00 UTC

    MoonLake Immunotherapeutics signed a Master Commercial Supply Agreement and a Capacity Agreement with Vetter Pharma International GmbH for the manufacture of pre-filled application systems and capacity reservation.